Patient: Page 3
-
Stock via Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024 -
Stock via Getty Images
Fresh data intensifies race for a major gene therapy target
4D Molecular Therapeutics reported positive interim analysis in the high-potential wet AMD indication last week.
By Meagan Parrish • Sept. 25, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Stock via Getty Images
Patient access: How Novartis, Eli Lilly, and other Big Pharmas measure up
A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in low- and middle-income countries.
By Alexandra Pecci • Sept. 23, 2024 -
Stock via Getty Images
The hunt for game-changers against the deadliest form of brain cancer
Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.
By Kelly Bilodeau • Sept. 16, 2024 -
stock.adobe.com/Syda Productions
Sponsored by LabConnectAgility in action: 5 ways to fast-track your clinical trial
Five ways to beat study timeline pressures and get medicines to patients faster.
Sept. 16, 2024 -
Permission granted by Organon
Why pharma should redefine ‘women’s health’
A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.
By Alexandra Pecci • Sept. 11, 2024 -
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
By Jonathan Gardner • Sept. 10, 2024 -
Permission granted by Reed Tuckson
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
By Michael Gibney • Aug. 15, 2024 -
Drew Angerer via Getty Images
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
The CEO noted how Pfizer's danuglipron could still be the second oral GLP-1 treatment to enter registrational tests after Lilly's orforglipron.
By Jonathan Gardner • Aug. 1, 2024 -
Douglas Cliff via Getty Images
As the GLP-1 market booms, other healthcare companies are cashing in
With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and foster new health benefits.
By Amy Baxter • July 10, 2024 -
Permission granted by Eli Lilly
FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.
Recent history suggests an Alzheimer’s approval doesn’t necessarily translate to market triumph. Perhaps for Eli Lilly’s Kisunla, this time could be different.
By Michael Gibney • July 9, 2024 -
Getty Images via Getty Images
The FDA pushes concrete plans to further diversity in clinical trials
The long-awaited guidance offers a more detailed road map for pharma.
By Kelly Bilodeau • July 8, 2024 -
Permission granted by Bristol-Myers Squibb
Ahead of its upcoming decision date, a competitor takes aim at KarXT
The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.
By Kelly Bilodeau • June 25, 2024 -
Jens Schluete via Getty Images
Q&ACan Moderna’s COVID-flu combo shot improve flagging vaccination rates?
A COVID and flu duo could ease manufacturing and administration, potentially driving higher vaccination rates, said Moderna’s VP of North American medical affairs.
By Michael Gibney • June 25, 2024 -
Stock via Getty Images
3 windows of opportunity in women’s health
Despite a recent surge of interest, the femtech and women’s health markets are far from reaching their full potential.
By Alexandra Pecci • June 21, 2024 -
Stock via Getty Images
NIH-funded trials fall flat on diversity goals
Many clinical trials aren’t meeting enrollment inclusion checkpoints — and some aren’t even setting targets, according to a recent OIG report.
By Amy Baxter • June 20, 2024 -
Stock via Getty Images
Pharma’s R&D gamble: picking pipeline winners in a risky field
How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.
By Meagan Parrish • June 7, 2024 -
Permission granted by City of Hope
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.
By Michael Gibney • June 6, 2024 -
Getty Images via Getty Images
Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field
Companies like UpScriptHealth led the charge with online prescriptions decades ago, and now the industry is catching on to solve some of healthcare’s most pressing issues.
By Michael Gibney • May 22, 2024 -
Jemal Countess via Getty Images
OpinionThe judicial microscope on abortion meds puts FDA and industry in a precarious spot
The recent SCOTUS case involving mifepristone exposes the risk of drug safety determinations by judicial fiat.
By Meg Alexander • May 9, 2024 -
Permission granted by AstraZeneca
Q&AAZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
By Michael Gibney • May 8, 2024 -
Mario Tama via Getty Images
Inside J&J’s strategy to de-gender clinical trials
Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.
By Alexandra Pecci • April 23, 2024 -
Permission granted by Amylyx Pharmaceuticals
Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug
Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.
By Meagan Parrish • April 19, 2024 -
Chris McGrath via Getty Images
Deep DiveUkraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
New clinical trial starts are picking back up, but are still far below their bustling pre-war level.
By Meagan Parrish • April 16, 2024 -
Stock via Getty Images
Where the GLP-1 weight loss market goes will depend on data
As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.
By Amy Baxter • April 15, 2024
Previous
